Ergomed PLC -.1% potential downside indicated by Investec Securities

Ergomed PLC with ticker (LON:ERGO) now has a potential downside of -.1% according to Investec Securities.



Investec Securities set a target price of 1,350 GBX for the company, which when compared to the Ergomed PLC share price of 1,352 GBX at opening today (19/09/2023) indicates a potential downside of -.1%. Trading has ranged between 895 (52 week low) and 1,380 (52 week high) with an average of 495,766 shares exchanging hands daily. The market capitalisation at the time of writing is £686,583,221.

Ergomed PLC is a United Kingdom-based company that is primarily focused on providing specialized services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company serves over 100 countries. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.